Biohaven CEO says drug approval is ‘monumental’ for migraine patients – CNBC

Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.
The U.S. Food and Drug Administration las… [+914 chars]

View The Article On: CNBC

Powered By

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

To Top